INNT
TOTAL INVALIDATION PROCESSED BY THE IB
26/04/2025
Voltar para busca
Dado oficial do USPTO
CAP GT
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
49
Atualização mais recente
27/04/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 42
Data de depósito
11/07/2016
Data de registro
31/10/2017
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
17/05/2024
Última transação
27/04/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
27
Localização do titular
DE
Examinador
CORWIN, KEVIN
Unidade examinadora
M30
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
CEVEC Pharmaceuticals GmbH
Representantes
Miriam D. Trudell Sheridan Ross P.C.
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicalbiological and biochemical productspreparations and reagents for scientificresearchlaboratoryindustrial and commercial purposesexcept chromatography chemicals and mediaexcept chemicals for use in separation and purification; chemicalbiological and biochemical productspreparations and reagents for researching and characterizing diseases except chromatography chemicals and mediaexcept chemicals for use in separation and purification; chemicalbiological and biochemical productspreparations and reagents for scientific and medical research and drug development except chromatography chemicals and mediaexcept chemicals for use in separation and purification; chemicalbiological and biochemical productspreparations and reagents for manufacturing drugs and pharmaceuticalsexcept chromatography chemicals and mediaexcept chemicals for use in separation and purification; micro-organismsproteinspolypeptidesnucleotidesnucleic acidseukaryotic cell lines and eukaryotic cells for scientificresearchlaboratoryindustrial and commercial purposes; all other than for medical or veterinary use
Classe 5
Medicines for the treatment and prevention of cancertumorous diseasesproliferative diseasesallergiesauto-immune diseasesinflammationinflammatory diseasesinfectious diseasesosteoporosisgraft versus host and host versus graft diseasestransplant rejectioncoronary heart diseasesminimal residual diseasesrestenosismetabolic disordersneurological disordersdiabetesB cell malignancyrheumatoid arthritisimmunological disordersparasitic reactionsskin diseasesneurodegenerative diseases and cardio-vascular diseasesexcept thyreostatics and cough and cold preparations; pharmaceutical and veterinary productspreparations and reagents for the treatment and prevention of cancertumorous diseasesproliferative diseasesallergiesauto-immune diseasesinflammationinflammatory diseasesinfectious diseasesosteoporosisgraft versus host and host versus graft diseasestransplant rejectioncoronary heart diseasesminimal residual diseasesrestenosismetabolic disordersneurological disordersdiabetesB cell malignancyrheumatoid arthritisimmunological disordersparasitic reactionsskin diseasesneurodegenerative diseases and cardio-vascular diseasesall afore mentioned goods except thyreostatics and cough and cold preparations; chemicalbiological and biochemical preparations for the treatment and prevention of cancertumorous diseasesproliferative diseasesallergiesauto-immune diseasesinflammationinflammatory diseasesinfectious diseasesosteoporosisgraft versus host and host versus graft diseasestransplant rejectioncoronary heart diseasesminimal residual diseasesrestenosismetabolic disordersneurological disordersdiabetesB cell malignancyrheumatoid arthritisimmunological disordersparasitic reactionsskin diseasesneurodegenerative diseases and cardio-vascular diseasespreparations and reagents for medical and veterinary purposes for the treatment and prevention of cancertumorous diseasesproliferative diseasesallergiesauto-immune diseasesinflammationinflammatory diseasesinfectious diseasesosteoporosisgraft versus host and host versus graft diseasestransplant rejectioncoronary heart diseasesminimal residual diseasesrestenosismetabolic disordersneurological disordersdiabetesB cell malignancyrheumatoid arthritisimmunological disordersparasitic reactionsskin diseasesneurodegenerative diseases and cardio-vascular diseasesexcept cough and cold preparationsexcept chromatography chemicals and mediaexcept chemicals for use in separation and purification; diagnostic and analytical preparations for medical and veterinary purposes for the treatment and prevention of cancertumorous diseasesproliferative diseasesallergiesauto-immune diseasesinflammationinflammatory diseasesinfectious diseasesosteoporosisgraft versus host and host versus graft diseasestransplant rejectioncoronary heart diseasesminimal residual diseasesrestenosismetabolic disordersneurological disordersdiabetesB cell malignancyrheumatoid arthritisimmunological disordersparasitic reactionsskin diseasesneurodegenerative diseases and cardio-vascular diseases; cultures of micro-organismsprotein arrayssynthetic polypeptidesnucleotide arraysnucleic acid sequenceeukaryotic cell lines and eukaryotic cells for medicalveterinary and diagnostic purposesexcept cough and cold preparations
Classe 42
Scientific and industrial researchin particular in the fields of medicinepharmacymolecular biologybiotechnology and genetics; research and development of drugsdiagnostic and analytical preparationstherapy procedures and expression systems; scientifictechnical and industrial consultancyin particular in the field of research medicinepharmacymolecular biologybiotechnology and genetics; scientific and industrial research and development of eukaryotic cell lineseukaryotic cellsmicro-organismspolypeptidesproteinsnucleotidesnucleic acidsfor third parties for scientificresearchlaboratory developmentindustrial and commercial purposesin particular for use in the field of medicinepharmacymolecular biologybiotechnology and geneticsexcept services relating to capture and intermediate purification of proteins
Publicações
Histórico de despachos e eventos da marca no USPTO.
49 publicações encontradas
INTS
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
06/04/2025
INPC
INVALIDATION PROCESSED
05/04/2025
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
18/01/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
18/10/2024
C71T
CANCELLED SECTION 71
17/05/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
19/11/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
21/08/2023
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
21/08/2023
EWOR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
21/08/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
21/08/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
21/08/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
21/08/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
21/08/2023
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
31/10/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
13/07/2021
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
13/07/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
13/07/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
13/07/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
11/06/2021
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
11/06/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
11/06/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
11/06/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
17/08/2018
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
30/03/2018
FICS
FINAL DISPOSITION NOTICE SENT TO IB
06/02/2018
FIMP
FINAL DISPOSITION PROCESSED
06/02/2018
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
31/01/2018
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
27/11/2017
R.PR
REGISTERED-PRINCIPAL REGISTER
31/10/2017
GPNX
NOTIFICATION PROCESSED BY IB
18/08/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
15/08/2017
PUBO
PUBLISHED FOR OPPOSITION
15/08/2017
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/08/2017
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
02/08/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
26/07/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/07/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
13/06/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
13/06/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
13/06/2017
RFNT
REFUSAL PROCESSED BY IB
20/01/2017
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
30/12/2016
RFRR
REFUSAL PROCESSED BY MPU
30/12/2016
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
28/12/2016
CNRT
NON-FINAL ACTION WRITTEN
27/12/2016
MAFR
APPLICATION FILING RECEIPT MAILED
20/12/2016
DOCK
ASSIGNED TO EXAMINER
15/12/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
15/12/2016
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/12/2016
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CAP GT ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.